KRAS G12D Inhibitor-induced Resistant Tumor Models

KRAS mutations act as primary initiators of carcinogenesis in several major cancers and are present in approximately 20 - 25% of all human tumors. KRAS G12D is the most frequent KRAS mutation in both colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC), driving tumor progression and acting as a key therapeutic target.

While KRAS G12D-selective inhibitors have shown promising antitumor activity in clinical trials, the development of acquired resistance is recognized as a challenge to long-term therapeutic effectiveness. To support research on developing targeted and combination therapies to overcome this resistance, WuXi Biology has established several KRAS G12D inhibitor–induced resistant tumor models.